CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing terpenoid-based nanoparticles for drug delivery, aiming to enhance treatment efficacy for severe diseases like cancer. By chemically linking terpenoids to drugs, the project seeks to create self-assembling nanoparticles that improve drug loading and targeting.
Terpenoids are a group of natural compounds that are extraordinary diverse in chemistry, structure and function.
Most of the natural terpenoids are flexible and biocompatible biopolymers, having physico-chemical characteristics able to adapt to a wide variety of biologically active compounds.
Surprisingly, they have never been used previously in the nanotechnology field for drug delivery and targeting purposes, except very recently by us to design squalene-based nanoassemblies.
Thus, the current…
UNIVERSITE PARIS-SUD
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
France, Montigny le Bretonneux
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Belgium, Louvain La Neuve
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
